- In men with hypogonadism, short-term testosterone treatment does not appear to increase cardiovascular or cerebrovascular event risk.
- Longer-term effects, if any, are unknown.
- Editorial advises waiting for 5-year TRAVERSE trial results before widespread testosterone therapy adoption.
Why this matters
- Testosterone has a variety of potentially contrasting influences on cardiovascular...